SightfileU.S. market data from official filings

Companies › AIM

AIM IMMUNOTECH INC (AIM)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0000946644 · EDGAR filings · Updated 2026-07-16

AIM IMMUNOTECH INC (AIM) has reported institutional ownership of 2.1%, with 17 institutional managers holding positions valued at $99.9K per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
2.1%
Institutional managers
17
Reported 13F value
$99.9K
Insider activity
10 trans.
$126.5K net buying
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, AIM IMMUNOTECH INC has 17 institutional holders and institutional ownership of 2.1%.

Insider activity

Insiders reported 10 transactions (5 buys, 0 sells) across 5 reporting insiders, with a net reported value of $126.5K.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-15 (recurring since 2020-03-30) — source filing. The authoritative details are those stated in the filing itself.

Related companies

ORAGENICS INC (OGEN) · Glucotrack Inc (GCTK) · Catheter Precision Inc (VTAK) · Jaguar Health Inc (JAGX) · Lifeward Inc (LFWD) · Co-Diagnostics Inc (CODX)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-16.